Lincoln Pharmaceuticals Limited (NSE:LINCOLN)

Market Cap	14.69B +29.9%
Revenue (ttm)	6.52B +9.1%
Net Income	878.34M -1.7%
EPS	43.85 -1.7%
Shares Out	n/a
PE Ratio	16.72
Forward PE	n/a
Dividend	1.80 (0.25%)
Ex-Dividend Date	Sep 12, 2025

Volume	138,907
Average Volume	286,115
Open	736.00
Previous Close	732.15
Day's Range	731.00 - 750.20
52-Week Range	440.00 - 749.70
Beta	0.40
RSI	68.01
Earnings Date	May 28, 2026

About Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East As...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1979
• Employees: 1,853
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LINCOLN

Financial Performance

In fiscal year 2025, Lincoln Pharmaceuticals's revenue was 6.23 billion, an increase of 7.35% compared to the previous year's 5.81 billion. Earnings were 823.46 million, a decrease of -11.74%.